Cyclobenzaprine Hydrochloride
Product Images NDC 50436-0401

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Cyclobenzaprine Hydrochloride (NDC 50436-0401). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (50436 0401 1)

Cyclobenzaprine Hydrochloride 10 mg tablet packaging label showing a 30-count unit dose container. The label includes drug name, strength, count, manufacturer Cipla USA Inc. in Warren, NJ, and storage instructions. It displays lot number, expiration date placeholders, barcode, and RX only designation.*

FDA Label Image

Image Description (50436 0401 3)

Cyclobenzaprine Hydrochloride 10 mg tablets packaging label showing a 90-tablet count. The label includes drug name, strength, dosage form, manufacturer Cipla USA, location Warren, NJ, and packaging by Unit Dose Services, LLC, Dania, FL. It features storage instructions, warnings, NDC 50436-0401-3, lot, and expiration placeholders.*

FDA Label Image

Image Description (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 01)

Chemical structure of Cyclobenzaprine Hydrochloride showing a three-ring fused aromatic system and side chain with a dimethylamine group, associated with hydrochloride.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 02)

A comparative data table showing the percentage incidence of side effects including drowsiness, dry mouth, fatigue, and headache among participants taking Cyclobenzaprine HCl 5 mg tablets, Cyclobenzaprine HCl 10 mg tablets, and placebo. The table includes the sample size for each group and lists side effect percentages for each category.*

FDA Label Image

Image (7d5e3bad 7f85 4e2b 81c5 7981c456e45f 03)

A table comparing the incidence rates of drowsiness, dry mouth, and dizziness in clinical studies versus a surveillance program for Cyclobenzaprine HCl Tablets, 10 mg. The table shows higher percentages of these side effects in clinical studies compared to the surveillance program.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.